Efficacy and safety of gefapixant for chronic cough: a meta-analysis of randomised controlled trials

Conclusions
This meta-analysis revealed dose-dependent efficacy and adverse effects of gefapixant against chronic cough. Further studies are required to investigate the feasibility of moderate-dose (i.e. 45–50 mg twice daily) gefapixant in clinical practice.

Source: European Respiratory Review - May 17, 2023 Category: Respiratory Medicine Authors: Chuang, M.-H., Chen, I.-W., Chen, J.-Y., Kang, F.-C., Ho, C.-N., Wu, S.-C., Yew, M., Lan, K.-M., Hung, K.-C. Tags: Pulmonary pharmacology and therapeutics, Respiratory clinical practice Reviews Source Type: research